SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing extreme volatility amid allegations of a pump-and-dump scheme, sparking intense debate between traders labeling it a fraudulent manipulation and those betting on its potential through upcoming event-driven catalysts. While proponents point to real-world integration and event partnerships as drivers for growth, the community remains deeply polarized over concerns regarding highly concentrated supply ownership and the potential for a sudden, sharp decline.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a historical artifact of crypto culture, with investors highlighting its 2011 origin and recent tokenization as evidence of its enduring relevance. The community is actively debating its potential to reach billion-dollar market status, citing accumulation by high-net-worth wallets and the narrative strength of being the original parody of Bitcoin.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is trending due to a significant policy shift following a new executive order that accelerates FDA review pathways for psychedelic-based therapies, including LSD. Investors are actively debating the potential for a sector-wide re-rating and identifying candidates for future M&A, as Definium remains in focus with multiple Phase 3 trial readouts scheduled throughout the year.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as investors digest a series of positive regulatory and clinical updates, including a significant executive order from the Trump administration aimed at accelerating FDA review processes for psychedelic-assisted therapies. Community sentiment is largely focused on the potential for reduced clinical timelines and the impact of upcoming late-stage trial readouts, fueling speculative volume and institutional interest in the broader psychedelic biotech sector.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is currently in the spotlight following the announcement of positive Phase 2 signal detection study results for its HLP004 anxiety therapeutic, even as investors grapple with significant volatility and the company's recent rebranding to the "HELP" ticker. Community discourse is sharply divided between long-term holders encouraged by institutional backing and a robust patent portfolio, and skeptical participants highlighting historical dilution concerns and the risks inherent in a clinical-stage biotech navigating a complex regulatory environment.

Procure ETF Trust II - Procure Space ETF

The Procure Space ETF ($UFO) is attracting significant community attention as investors position themselves for the potential IPO of SpaceX and the broader expansion of the commercial space economy. While some community members appreciate the ETF for its broad exposure to industry leaders, others are debating whether its diverse holdings truly constitute a 'pure play' on space, leading to discussions about alternative investment strategies.

Roundhill ETF Trust - Roundhill Ether Covered Call Strategy ETF

oundhill Ether Covered Call Strategy ETF

The community is actively monitoring the Roundhill Ether Covered Call Strategy ETF for its consistent weekly dividend distributions, despite varied sentiment regarding the fund's net asset value performance. Investors are balancing the appeal of high-yield income strategies against the inherent volatility of the underlying Ethereum market as they track upcoming distribution announcements.

Peanut the Squirrel Markets

The community is actively debating the recent price action of PNUT, with many participants viewing recent pullbacks as buying opportunities while others discuss its potential for a relief bounce toward higher resistance levels. Sentiment is heavily polarized between long-term holders eyeing significant valuation milestones and traders capitalizing on high-frequency volatility within the broader meme coin rotation.

Tidal Trust II - Defiance Daily Target 2X Long IONQ ETF

Defiance Daily Target 2X Long IONQ ETF

IONX is trending as investors actively track its performance as a 2x leveraged play on IonQ, frequently debating its volatility and potential for significant gains against the underlying stock's technical movements. The community is focused on using this ETF for aggressive scalping and swing trading strategies, often weighing its rapid price fluctuations against the broader operational milestones and market outlook for the quantum computing sector.

Loopring is a Decentralized Exchange (DEX) built on an Ethereum Layer-2 (L2) solution called zkRollup. It has both Automated Market Maker (AMM)-based and orderbook-based exchanges.&nbsp;  zkRollup is an Ethereum L2 scaling solution that migrates computations off the blockchain. Loopring protocol only uses the underlying Ethereum blockchain as a data layer and a verification layer. As a result, Loopring's throughput is as high as 2,025 trades per second compared to Ethereum’s current throughput of 15 transactions per second. The result is that the cost per trade settlement is as small as $0.00015.  Loopring's performance is sufficient for professional traders and market makers to deploy algorithmic strategies and other automated trading bots. This was not previously possible on any DEX as it was prohibitively slow and expensive. By building on top of Loopring 3.0, orderbook-based DEXs can be commercially viable for the first time. Loopring expects non-custodial exchanges can begin to outcompete and displace many centralized counterparts.

Loopring

Loopring is seeing renewed interest as the community speculates on a potential breakout, driven by historical cycles and ongoing debates over its future role within decentralized ecosystems. While long-term holders remain focused on structural gains, discussions are split between optimistic calls for a rally and skepticism regarding the project's utility and market performance compared to broader altcoin trends.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Biotech Stocks To Consider - April 18th

Danaher, Moderna, Vertex Pharmaceuticals, United Therapeutics, Medpace, argenex, and Flag Ship Acquisition are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool...

Mirae Asset Global Investments Co. Ltd. Grows Holdings in Danaher Corporation $DHR

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 41.8% during the 4th quarter, according to the company in its most recent 13F...

Danaher Corporation (NYSE:DHR) Given Consensus Rating of "Moderate Buy" by Brokerages

Shares of Danaher Corporation (NYSE:DHR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-one ratings firms that are currently covering the company, MarketBeat...

<ul class="summary-bullets"><li>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher, accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed.</li><li>Masimo can appeal the ITC's decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.</li></ul>The U.S. International Trade Commission has ruled in favor of Apple (AAPL), rejecting medical-device maker Masimo’s (MASI) latest attempt to impose a fresh import ban on certain Apple Watch models.The commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. The judge had found that Apple’s redesigned smartwatches do not infringe two Masimo patents covering blood-oxygen measurement technology.“For more than six years, Masimo has waged a relentless legal campaign against Apple, and nearly all of its claims have been rejected,” Apple reportedly said in a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/apple-defeats-bid-new-apple-watch-import-ban-us-trade-tribunal-2026-04-17/">statement</a> to Reuters while extending its gratitude to the commission.<h2 class="st-heading-2">Apple Vs. Masimo</h2>The dispute between the two firms began in 2021 when Masimo, which is being acquired by Danaher (DHR), accused Apple of poaching key engineers and stealing pulse-oximetry technology it had developed for hospital-grade monitors. Masimo claimed Apple used the know-how to launch the blood-oxygen feature on the Apple Watch. The Irvine, California-based company filed patent-infringement and trade-secret lawsuits in California federal court and a separate complaint at the U.S. International Trade Commission.In December 2023, the ITC sided with Masimo, imposing an import ban on Apple Watch Series 9 and Ultra 2 models that used the blood-oxygen sensor. Apple subsequently disabled the feature in America while it developed a redesign.Apple’s redesign was approved by the U.S. Customs and Border Protection in August 2025. However, Masimo challenged that redesign at the ITC, leading up to the events on Friday.Masimo can appeal the decision to the Washington-based U.S. ​Court of Appeals for the Federal Circuit, Reuters noted.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MASI and AAPL stocks stayed within the ‘bullish’ territory at the time of writing.While <a href="https://stocktwits.com/symbol/MASI">MASI stock</a> has gained 17% over the past 12 months, <a href="https://stocktwits.com/symbol/AAPL">AAPL stock </a>has gained 37%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/sls-stock-sparks-retail-buzz-ahead-of-aacr-presentation-on-experimental-cancer-therapy/cZJy282RIUY">SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A new Apple Watch is displayed during an Apple special event at Apple headquarters on September 9, 2025 in Cupertino, California.  

Apple Clears Major Legal Hurdle After U.S. Trade Tribunal Shuts Down Masimo’s Latest Watch Ban Attempt

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 

Equity

The U.S. International Trade Commission closed Masimo’s case after declining to review a preliminary ruling issued in March by an ITC administrative law judge. 


Top Biotech Stocks To Watch Now - April 17th

Danaher, United Therapeutics, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that apply...

Danaher Corporation $DHR Stake Lifted by Whittier Trust Co.

Whittier Trust Co. increased its stake in Danaher Corporation (NYSE:DHR - Free Report) by 12.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange...

KBC Group NV Has $65.13 Million Stock Holdings in Danaher Corporation $DHR

KBC Group NV boosted its stake in Danaher Corporation (NYSE:DHR - Free Report) by 6.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission...

Lbp Am Sa Purchases 46,347 Shares of Danaher Corporation $DHR

Lbp Am Sa grew its position in Danaher Corporation (NYSE:DHR - Free Report) by 422.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The...

Fisher Funds Management LTD Has $91.23 Million Stock Position in Danaher Corporation $DHR

Fisher Funds Management LTD lessened its position in shares of Danaher Corporation (NYSE:DHR - Free Report) by 26.0% in the fourth quarter, according to the company in its most recent 13F filing with...

Danaher Corporation (NYSE:DHR) Short Interest Up 25.0% in March

Danaher Corporation (NYSE:DHR - Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 6,939,368 shares, a growth of 25.0% from the March...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

DHR
Danaher Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DHR News

DHRDanaher Corp.